MEI Pharma, Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 6 of 6 Posts
Week In Review: Biosense Exercises $75 Million Option For China Rights To Neovacs' Lupus Immunotherapy
Article By: ChinaBio® Today Saturday, October 13, 2018 4:59 PM EST
Biosense Global, a New Jersey-Suzhou in-licensing company, exercised a $75 million option for China rights to an active lupus immunotherapy developed by Neovacs, following a successful Phase II trial of the therapeutic vaccine, IFNalpha Kinoid.
In this article: MEIP, BGNE
Read
Buying Stocks Below Their Cash Value
Article By: Fred Fuld Monday, October 9, 2017 8:30 PM EST
There are numerous risks and advantages to buying below cash stocks. To learn more about this investment strategy as well as some real life examples, read on.
In this article: GENC, BEBE, SPRT, MEIP, RUBI
Read
E MEI Pharma Signs Licensing Deal, Soars Higher
Article By: Terry Chrisomalis Monday, August 8, 2016 10:42 PM EST
The announcement of MEIP's license agreement with Swiss pharma group Helsinn put the stock up more than 48% premarket, ending the day up just shy of 28%.
In this article: MEIP
Read
Why MEI Pharma Is Likely To Rally Over $3 In The Next Month Or So
Video By: StockMatusow Thursday, May 7, 2015 11:10 AM EST
In this video, I explain why I like the MEIP chart and why I think it will rally over $3 in the next 3 to 4 weeks .
In this video: MEIP Also: SGYP, IBB
Watch
MEI Pharma Is Oversold And Will Recover
Article By: StockMatusow Wednesday, April 1, 2015 12:02 PM EST
Recently, MEI Pharma reported that its Phase II trial for Pracinostat in combination with azacitidine failed to meet its primary endpoint. However, Pracinostat has been shown to work in a 2nd line setting. With catalysts upcoming, the stock is oversold and half valued and should rally back.
In this article: MEIP, FOLD, ACAD
Read
Institutions Buying MEI Pharma Ahead Of Topline Data Catalyst In Mid-March
Article By: StockMatusow Wednesday, February 25, 2015 1:44 PM EST
MEIP is expecting to release important Phase II topline data next month. We expect to see the stock price continue to increase up until that time. If positive as we expect, the stock should even rally further.
In this article: CELGZ, ONTX, CELG, MEIP
Read
1 to 6 of 6 Posts